By addressing key mechanisms of immune evasion, Biond’s approach is designed to unlock durable and clinically meaningful responses in patients with high unmet clinical need.
Biond is also are advancing a portfolio of innovative programs in immune-mediated diseases, expanding the impact of our science beyond oncology.
Biond Biologics Ltd., Misgav Industrial Park, Israel